ArticleVirology2013
Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters.
Article in Virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 46 citations in OpenAlex.
- Cooperative clamp-mediated promoter recognition by poxviral RNA polymerase and its TBP/TFIIB-like partner.Nature communications · 2026Article
- Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform.Frontiers in immunology · 2026Review
- Vaccinia Virus-A Swiss Army Knife Against Cancer.Cancers · 2025Review
- Nonredundant roles of topoisomerase 2α and 2β in the cytosolic replication of vaccinia virus.Nucleic acids research · 2025Article
- Temporal expression classes and functions of vaccinia virus and mpox (monkeypox) virus genes.mBio · 2025Review
- Construction and Isolation of Recombinant Vaccinia Virus by Homologous Recombination Using Fluorescent Protein Markers.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.Viruses · 2024Review
- La-related protein 4 is enriched in vaccinia virus factories and is required for efficient viral replication in primary human fibroblasts.Microbiology spectrum · 2023Article
- Better late than never: A unique strategy for late gene transcription in the beta- and gammaherpesviruses.Seminars in cell & developmental biology · 2023Review
- Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice.Pathogens (Basel, Switzerland) · 2023Article
- ISG15 Is Required for the Dissemination of Vaccinia Virus Extracellular Virions.Microbiology spectrum · 2023Article
- In-depth Temporal Transcriptome Profiling of Monkeypox and Host Cells using Nanopore Sequencing.Scientific data · 2023Article
- La-related protein 4 is enriched in vaccinia virus factories and is required for efficient viral replication in primary human fibroblasts.bioRxiv : the preprint server for biology · 2023Article
- Why do poxviruses still matter?Cell & bioscience · 2021Review
- Genomic Characterisation of a Novel Avipoxvirus Isolated from an Endangered Northern Royal Albatross (Pathogens (Basel, Switzerland) · 2021Article
- Genomic Characterisation of a Novel Avipoxvirus Isolated from an Endangered Yellow-Eyed Penguin (Viruses · 2021Article
- Mucosal and Systemic Immune Responses to Salmon Gill Poxvirus Infection in Atlantic Salmon Are Modulated Upon Hydrocortisone Injection.Frontiers in immunology · 2021Article
- Transcriptome view of a killer: African swine fever virus.Biochemical Society transactions · 2020Review
- Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges.Cancers · 2020Review
- Vaccinia Virus as a Master of Host Shutoff Induction: Targeting Processes of the Central Dogma and Beyond.Pathogens (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Vaccinia virus contains ~200 genes classified temporally as early, intermediate or late. We analyzed 53 intermediate promoters to determine whether any have dual late promoter activity. Our strategy involved (i) construction of a cell line that stably expressed the three late transcription factors, (ii) infection with a vaccinia virus mutant that expresses RNA polymerase but neither intermediate nor late transcription factors, and (iii) transfection with plasmids containing a luciferase reporter regulated by an intermediate promoter. After confirming the specificity of the system for late promoters, we found that many intermediate promoters had late promoter activity, the strength of which correlated with a TAAAT at the initiator site and T-content from positions -12 to -8 of the coding strand. In contrast, intermediate promoter activity correlated with the A-content from positions -22 to -14. The sequence correlations were confirmed by altering the specificities of strict intermediate and late promoters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.